Pharma's Almanac TV
PA TV
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Drug Development
594 Articles Available
1
25
Can't find what you're looking for? Try our
advanced search
.
COVID-19 Trial Data
Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19
PR-M07-20-NI-015
Capacity Expansion
Vetter Further Expands its Development Service with New Site in Austria
PR-M07-20-NI-010
Chronokines
Delivering Breakthrough Medicines for Rare Hematologic Diseases and Cancers
PAP-Q2-20-CL-003
Antibody–Drug Conjugates
Linking Novel Medicines to Patients with Hard-to-Treat Cancers for Improved Quality of Life
PAP-Q2-20-CL-012
Chronokines
Solving Unmet Clinical Needs by Harnessing the Science of Aging
PAP-Q2-20-CL-013
Cancer Therapies
Computational Discoveries for Clinical Development of Novel Cancer Therapies
PAP-Q2-20-CL-014
Drug Repositioning
A Therapeutic Strategy for Neurological Disorders
PAP-Q2-20-CL-016
Immunotherapy
Leveraging the Native Immune Response to Fight Cancer
PAP-Q2-20-CL-017
Novel Antibiotics
Applying A Synthetic Approach To The Development Of A New Generation Of Antibiotics
PAP-Q2-20-CL-019
In Conversation
In Conversation: Novel Off-The-Shelf Targeted Cell Therapies
PAP-Q2-20-CL-021
Epigenetics
Epigenetic Regulation to Treat Acute Organ Injury and Chronic Liver Diseases
PAP-Q2-20-CL-022
Endocrine Diseases
Developing Transformative Treatments for Rare Endocrine Diseases
PAP-Q2-20-CL-023
Cancer and Neurodegenerative Diseases
Leveraging the Cell Cytoskeleton for the Treatment of Cancer and Neurodegenerative Diseases
PAP-Q2-20-CL-024
Coping with COVID-19
COVID-19: Understanding the Virus, the Pandemic, and the Path Forward
PAP-Q2-20-NI-004
Roundtable
Q: What two or three drug molecules do you identify as having had the greatest impact on society? What about on the pharmaceutical industry?
PAP-Q2-20-RT-002
Oncology
Eli Lilly Drug Significantly Reduces the Risk of Breast Cancer Returning
PR-M06-20-NI-020
COVID-19
Low-cost Dexamethasone Reduces Death in Patients with Severe Respiratory Complications of COVID-19
PR-M06-20-NI-018
Gene Editing
Vertex Announces New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies
PR-M06-20-NI-017
Oncology
Calquence Showed Long-Term Efficacy and Tolerability for Patients with Chronic Lymphocytic Leukemia in Two Trials
PR-M06-20-NI-019
HIV
ViiV Healthcare’s Injectable Formulation Dosed Every Two Months Shows Higher Efficacy than Daily Oral PrEP
PR-M05-20-NI-034
Innovation
HKBU Scientists Eliminate Drug Side Effects by Manipulating Molecular Chirality
PR-M05-20-NI-029
Cancer Treatment
HKBU-led Research Team Develops Novel Anti-viral Targeted Drug for Nasopharyngeal Cancer Treatment
PR-M05-20-NI-024
Clinical Trials
MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 Clinical Trial for the Treatment of Obstructive Hypertrophic Cardiomyopathy
PR-M05-20-NI-021
COVID-19 Treatment
Mylan to Supply Investigational Antiviral Remdesivir for the Potential Treatment of COVID-19
PR-M05-20-NI-018
1
25
»
